LANCL2

Across TCGA pan-cancer cohorts, LANCL2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of LANCL2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where LANCL2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types LANCL2 is over-expressed in tumor, although a few such as COAD and CCRCC show the opposite, repressed pattern.

COAD, CCRCC, and PDAC are the cancer types where LANCL2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LANCL2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	III,IV	−0.368	<.001	10	view →
CCRCC	Male	II,III,IV	−0.167	<.001	10	view →
PDAC	Female	II,III,IV	−0.489	<.001	8	view →
HNSC	All	III,IV	+0.252	.049	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

LANCL2–COAD

Open the COAD breakdown →